Human monoclonal antibodies to CD70
US8124738B2 · kind B2 · utility
51Cited by
25References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2006 |
| Grant date | Feb 28, 2012 |
| Priority date | — |
| Expiry date | Sep 3, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.